ReviewCureus2024
Catastrophic Antiphospholipid Syndrome: A Review of Current Evidence and Future Management Practices.
Review in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Article
- Rare Pediatric Male Presentation of Systemic Lupus Erythematosus With Catastrophic Antiphospholipid Syndrome Following Pulmonary Tuberculosis: A Case Report.Clinical case reports · 2026Article
- Catastrophic Antiphospholipid Syndrome in a Young Female Complicated by Systemic Lupus Erythematosus and Left Atrial Myxoma: A Rare Case Report.Clinical case reports · 2026Article
- Imaging features of catastrophic antiphospholipid syndrome : Massive saddle pulmonary embolism with subsequent complete resolution.Radiology case reports · 2026Article
- The catastrophe of catastrophic antiphospholipid syndrome: a case report.European heart journal. Case reports · 2026Article
- Uncommon clinical presentations and diagnostic difficulties of antiphospholipid syndrome associated withMedical mycology case reports · 2026Article
- Designing a rheumatology and immunology nursing training model for resource-limited settings: application of the Medical Research Council framework.Frontiers in medicine · 2026Article
- Case report of a fatal probable catastrophic antiphospholipid syndrome.Frontiers in medicine · 2026Article
- Role of antiphospholipid antibodies in kidney disease: Risk factors, immunopathogenesis, and diagnosis.World journal of nephrology · 2025Review
- Intensive care unit admission and mortality in rheumatic diseases.Rheumatology international · 2025Review
- Kidney and Pregnancy: A Comprehensive Review.Clinics and practice · 2025Review
- Article
- Pathological Study of a Case of Catastrophic Antiphospholipid Syndrome in a Patient With Gastrointestinal Bleeding.Cureus · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by blood clots and pregnancy complications due to antiphospholipid antibodies. Catastrophic APS (CAPS), a severe variant, leads to multiorgan failure and is often fatal. Pathogenesis involves antiphospholipid antibodies, particularly anti-beta-2-glycoprotein I (aβ2GPI), which trigger endothelial cell (EC) activation, cytokine release, and a prothrombotic state. Infections, surgeries, and other triggers can precipitate CAPS, leading to widespread microthromboses and systemic inflammatory responses. CAPS predominantly affects younger patients and those with systemic lupus erythematosus (SLE), with a high mortality rate, though recent treatment advances have improved survival. Diagnosing CAPS involves identifying clinical manifestations, including rapid organ involvement and small vessel occlusions, confirmed by histopathology and high antiphospholipid antibody levels. The CAPS registry data indicate that commonly affected organs include kidneys, lungs, central nervous system, and the heart, with a high prevalence of lupus anticoagulant and anticardiolipin antibodies (aCL). Current management strategies focus on therapeutic anticoagulation, immunosuppressive therapies like corticosteroids, and adjunct treatments such as plasmapheresis and intravenous immunoglobulin (IVIG). Early use of glucocorticoids and combination therapy has significantly improved outcomes. In life-threatening cases, especially with microangiopathy, experts recommend performing plasma exchange (PE). Patients with associated autoimmune conditions or refractory cases may receive cyclophosphamide (CY) and rituximab while considering PE for treatment. Maintenance of anticoagulation with an appropriate international normalized ratio (INR) is crucial to prevent recurrence. This article reviews the pathogenesis and epidemiology of CAPS. It also examines the current management strategies, and discusses the challenges and controversies associated with these strategies. It hereafter offers recommendations for future management and outlines directions for further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.